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Abstract
Background: Thiazolidinediones (TZDs), rosiglitazone (RGZ) and pioglitazone (PGZ) are widely used as
hypoglycemic drugs in patients with type 2 diabetes mellitus. The aim of our study was to investigate the profile
of adverse drug reactions (ADRs) related to TZDs and to investigate potential risk factors of these ADRs.
Methods: Type 2 diabetic patients were identified from the French Database of PharmacoVigilance (FPVD)
between 2002 and 2006. We investigated ADR related to TZD, focusing on 4 ADR: edema, heart failure, myocardial
infarction and hepatitis corresponding to specific WHO-ART terms.
Results: Among a total of 99,284 adult patients in the FPVD, 2295 reports concerned type 2 diabetic patients (2.3%
of the whole database), with 161 (7%) exposed to TZDs. The frequency of edema and cardiac failure was
significantly higher with TZDs than in other patients (18% and 7.4% versus 0.8% and 0.1% respectively, p < 0.001)
whereas the frequency of hepatitis was similar (5.9% versus 4%, NS). A multiple logistic regression model taking
into account potential confounding factors (age, gender, drug exposure and co-morbidities) found that TZD
exposure remained associated with heart failure and edema, but not with hepatitis or myocardial infarction.
Conclusions: Thiazolidinediones exposure is associated with an increased risk of edema and heart failure in
patients with type 2 diabetes even when recommendations for use are respected. In contrast, the risk of hepatic
reactions and myocardial infarction with this class of drugs seems to be similar to other hypoglycemic agents.
Background
Thiazolidinediones (TZDs) are peroxisome proliferator-
activated receptor (PPAR) agonists which regulate tran-
scription of genes encoding proteins involved in glucose
and lipid metabolism. Troglitazone, the first agent of
this class, caused serious liver toxicity leading to its
withdrawal in 2000, less than 3 years after its marketing
[1]. The use of the 2 other TZDs, rosiglitazone (RGZ)
and pioglitazone (PGZ), has sharply increased during
the last few years. These 2 drugs seem to present a
lower risk of hepatotoxicity than troglitazone [2].
TZDs could also induce adverse drug reactions
(ADRs) related to the cardiovascular system including
edema and heart failure [3,4]. Edema is more frequent
when the TZD is used in combination therapy and its
incidence is higher in association with insulin. [4].
Because of the risk of congestive heart failure [5], the
use of RGZ and PGZ was initially contraindicated in
France in patients with a cardiac insufficiency corre-
sponding to classes I to IV of the NYHA classification.
The European Medicines Agency recommended the sus-
pension of marketing authorizations for rosiglitazone-
containing anti-diabetes medicines in Europe in Septem-
ber 2010 [6]. This decision followed the publication of 2
studies finding an increased cardiovascular risk of rosi-
glitazone [7,8]. In view of the restrictions already in
place on the use of rosiglitazone in Europe, no addi-
tional measures have been identified that could reduce
this cardiovascular risk.
The aim of our study was to investigate the profile of
adverse drug reactions (ADRs) related to TZDs as
reported to the French PharmacoVigilance System in type
2 diabetic patients, with a special focus on congestive
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any medium, provided the original work is properly cited.heart failure and myocardial infarction, and to investigate
factors associated with these ADRs.
Methods
We used the data from the French national system of
PharmacoVigilance, which has been described before
[9,10]. All suspected ADRs are evaluated using a French
standardized scale of causality assessment and registered
in the French PharmacoVigilance Database (FPVD) [11].
For each report, information on patient’s data (age, gender,
medical history) and drug exposure (suspected and conco-
mitantly used drugs) is recorded along with a brief clinical
description. ADRs are coded according to ADR Terminol-
ogy of the World Health Organization (WHO-ART) [12].
RGZ was the first TZD marketed at the end of 2001
in France. Therefore we performed searches in the
French PharmacoVigilance Database for ADRs reported
from January 2002 to December 2006. Among all cases
of ADRs reported in the database, patients exposed to
drugs approved in the treatment of diabetes in France
were short-listed, and we selected only patients with
type 2 diabetes. The following data were collected: age,
gender, medical history (coded ICD 10
th), and all drugs
(coded according to the ATC classification) used,
whether or not they were related to the present ADR.
Several co morbidities were identified from medical his-
tory and use of drugs. The ADR were described accord-
ing to the WHO-ART classification and presented as
SOC terms. Several WHO-ART codes were retained to
specifically describe edema (SOC term cardiovascular
disorders and metabolic and nutritional disorders:
edema, peripheral edema, low limbs edema), heart fail-
ure (SOC term cardiovascular disorders: cardiac failure,
congestive cardiac failure, pulmonary edema), myocar-
dial infarction (SOC term cardiovascular disorders and
myocardia : myocardial infarction, cardiac death), and
hepatitis (SOC term Liver and biliary system disorders:
abnormal hepatic functions, abnormal ASAT-ALAT
values, hepatitis).
The demographic and clinical characteristics of diabetic
patients exposed and non-exposed to TZDs were com-
pared using the c2t e s to rF i s h e r ’s exact test for qualita-
tive variables and using the Student’st - t e s tf o r
quantitative variables. In a further step, association
between use of TZDs and occurrence of edema, hepatitis,
cardiac failure or myocardial infarction was examined in
a bivariate analysis. In order to take into account poten-
tial confounding factors (age, gender, cardiovascular co-
morbidities and other drugs), a multivariate analysis was
performed using a backward logistic regression model.
The Hosmer and Lemeshow procedure [13] was used to
check the good fitting of the models. All analyses were
done with the SAS
® software version 9.1.
Results
Out of 99,284 adult patients registered in the FPVD
between January 2002 and December 2006, 2295 were
patients with type 2 diabetes (2.3% of the database).
Table 1 presents the demographic and clinical charac-
teristics of this population: half of the patients were
men; the mean age was 67 (± 13) years, they presented
a high frequency of comorbidities, with 27.0% suffering
from other metabolic disorders than diabetes, 25.9%
with previous heart attack, and 10.8% with cardiac insuf-
ficiency. Half of the population was exposed to sulfa-
mides, 40% to metformin and 5% was also treated with
insulin. One hundred and sixty-one patients (7%) were
exposed to TZDs: 46.6% used pioglitazone, 44.7% used
rosiglitazone, and 11.2% used roziglitazone + metformin
(4 patients were exposed successively to rosiglitazone
alone then to roziglitazone + metformin). These patients
were younger, less frequently exposed to sulfamides and
glinides, to statins and to NSAIDs than other diabetic
patients. They presented less frequently cardiac insuffi-
ciency, but they were more frequently obese.
The number of reports containing ADRs related to
TZDs increased from 2002 to the end of 2006, with 4
reports in 2002, 25 in 2003, 29 in 2004, 45 in 2005 and
58 in 2006 (Figure 1). Table 2 presents the most reported
ADR which concerned “Body as a whole - general disor-
ders”, followed by “Metabolic and nutritional disorders”,
“Cardiovascular disorders” and “Skin and appendages dis-
orders”. Among the 5 ADRs related to sense disorders, 4
were macular edema, and there was no report of frac-
tures. The degree of seriousness of reactions was similar
whatever the groups, with 2.53% of ADR leading to
death, 6.93% life-threatening, 0.61% leading to sequellae
or disability, except for ADRs leading to hospitalization
which were less frequent in TZD exposed patients
(40.37% versus 53.51%, p < 0.0001) and non-serious
A D R sw h i c hw e r em o r ef r e q u e n ti nT Z De x p o s e d
patients (53.42% versus 36.13%, p < 0.0001).
When considering specific ADR, heart failure was sig-
nificantly more frequent in TZD patients (5 exposed to
RGZ and 7 exposed to PGZ, 7.45% versus 0.14% in non-
exposed patients; p < 0.001), as well as edema (9
exposed to RGZ and 20 to PGZ, 18.01% versus 0.84% in
non-exposed patients; p < 0.0001). We did not find any
difference for hepatitis (4 patients exposed to RGZ and
4 to PGZ 4.97% versus 5.39% in non-exposed patients)
and for myocardial infarction (only 1 case exposed to
PGZ 0.62% versus 1.18% in non-exposed patients).
Table 3 presents the results of the multivariate analysis
concerning the association between TZD exposure and 4
ADRs: heart failure, myocardial infarction, edema and
hepatitis. Only edema and heart failure were significantly
and independently associated with TZD respectively with
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associated with heart failure, and obesity with edema.
Patients treated with biguanides were less exposed to
risk of edema. We did not find any association
between TZD and myocardial infarction (only heart
Table 1 Demographic and clinical characteristics of
patients identified in the French PharmacoVigilance
Database with type 2 diabetes
Total
population N
= 2295 (%)
TZD
exposed N
= 161 (%)
TZD not
exposed N =
2134 (%)
Age (years) 67.2 (13.4)
[19-97]
63.3 (14.2)
****
[32-87]
67.5 (13.8)
[19-97]
Gender (men) 1155 (49.7) 92 (57.1) 1063 (49.8)
Cardiovascular
comorbidities
Cardiac arrhythmia 128 (5.58) 8 (5) 120 (5.6)
Cardiac insufficiency 248 (10.81) 9 (5.6)* 239 (11.2)
Hypertension 596 (25.97) 33 (20.5) 563 (26.4)
Metabolic disorders 621 (27.06) 30 (18.7)* 591 (27.7)
Angina pectoris 154 (6.71) 6 (3.7) 148 (6.9)
Atherosclerosis 6 (0.26) 0 (0) 6 (0.28)
Obesity 76 (3.31) 10 (6.2)* 66 (3.1)
Heart valve disorders 7 (0.31) 1 (0.6) 6 (0.28)
Renal disorders 62 (2.7) 2 (1.2) 60 (2.8)
Drugs used for type 2
diabetes
Sulfamides 1227 (53.46) 44 (27.33)
****
1183 (55.43)
Alpha glucosidase
inhibitor
207 (9.02) 4 (2.48)** 203 (9.5)
Glinides 192 (8.37) 6 (3.7)* 186 (8.7)
Metformin 900 (39.22) 58(36) 842 (39.5)
Benfluorex 227 (9.89) 4 (2.5)** 223 (10.45)
Insulin 115 (5.01) 4 (2.94) 111 (5.20)
Cardiovascular drugs
Diuretics 627 (27.32) 34 (21.1) 593 (27.7)
ACE inhibitors 456 (19.87) 20 (12.4)* 436 (20.4)
Angiotensin II inhibitors 339 (14.77) 23 (14.3) 316 (14.8)
Digitalics 105 (4.58) 3 (1.9) 102 (4.8)
Betablockers 300 (13.07) 9 (5.6)** 291 (13.6)
Calcium inhibitors 321 (13.99) 16 (9.94) 305 (14.3)
Trinitrin 48 (2.09) 3 (1.9) 45 (2.1)
Amiodarone 103 (4.49) 2 (1.24)* 101 (4.73)
Central antihypertensive
drugs
73 (3.18) 5 (3.1) 68 (3.2)
Antiarrythmia drugs 25 (1.09) 1 (0.6) 24 (1.12)
Other drugs
Steroidal and Non
Steroidal Anti-
Inflammatory Drugs
232 (10.1) 8 (4.96)* 224 (10.5)
Statins 403 (17.56) 17 (10.6)* 386 (16.8)
Fibrates 142 (6.19) 7 (4.35 135 (6.3)
* p < 0.05.
** p < 0.01.
*** p <0.001.
**** p < 0.0001.
Quantitative variables are presented as mean (SD), [min-max] and qualitative
variables as number (%).
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Figure 1 Evolution of the total number of patients exposed to
Thiazolidinediones (TZD) in France and of the total number of
Adverse Drug Reactions (ADR) reported to the French
PharmacoVigilance Database in type 2 diabetic patients and in
TZD exposed patients.
Table 2 Number and percentage of adverse drug
reactions reported in the 161 patients exposed to
thiazolidinediones in the French PharmacoVigilance
database from 2002 to 2006
System Organ Classification terms Number of
patients (%)
Body as a whole - general disorders 1810 69 (42.8)
Metabolic and nutritional disorders 0800 64 (39.7)
Cardiovascular disorders, general 1010; Myo-, endo-,
pericardial & valve disorders 1020; Heart rate and
rhythm disorders 1030
42 (26.1)
Skin and appendages disorders 0100 35 (21.7)
Central & peripheral nervous system disorders 0410 33 (20.5)
Red blood cell disorders 1210; White cell and
reticulo-endotelial system disorders 1220; Platelet,
bleeding & clotting disorders 1230
26 (16.1)
Gastro-intestinal system disorders 0600 21 (13.0)
Liver and biliary system disorders 0700 15 (9.3)
Psychiatric disorders 0500 13 (8.1)
Respiratory system disorders 1100 11 (6.8)
Urinary system disorders 1300 7 (4.3)
Vascular (extra-cardiac) disorders 1040 6 (3.7)
Vision disorders 0431; Hearing and vestibular
disorders 0432; Special senses other, disorders 0433
5 (3.1)
Endocrine disorders 0900 4 (2.5)
Immune system 3 (1.9)
Muscular-skeletal system disorders 0200 2 (1.2)
Fetal disorders 1500 2 (1.2)
Total number of adverse drug reactions 358
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tis (as expected, there was a significant association
between hepatitis and NSAID).
Discussion
Among this population of diabetic patients registered in
the French Pharmacovigilance database due to the
occurrence of an adverse drug reaction, seven percent
was exposed to TZDs. In these patients, the reactions
were less frequently serious than in patients exposed to
other antidiabetic agents. TZD exposure is associated
with edema and heart failure in patients with type 2 dia-
betes, but the risk of hepatic reactions or myocardial
infarction with this class of drugs is the same with other
hypoglycemic agents.
TZDs can potentially lead to the development of con-
gestive heart failure [1]. In clinical trials, the incidence of
edema ranged from 2 to 5% in TZD monotherapy, 6 to
8% with metformin or sulfonylurea and 15% in combina-
tion with insulin. In our study, edema represented 18% of
ADR related to TZD, and concerned mainly patients
e x p o s e dt oP G Z .F l u i dr e t e n t i o nc a no c c u re v e na tt h e
lowest TZD dose, and diuretics and ACE inhibitors have
variable effects on edema caused by TZDs [1,3].
We found only one case of myocardial infarction in a
patient exposed to PGZ, and this event should not be
related to this drug. It concerned a 46-year-old man,
treated by lamivudine-zidovudine-nevirapine for a HIV
infection, and presenting high serum levels of triglycer-
ides 4,57 mmol/l (N< 1,74 mmol/l), cholesterol 8,80
mmol/l (N< 6,56 mmol/l), with a normal value for
HDL-cholesterol. He was also treated by glicazide and
benfluorex. After one year of treatment with TGZ, he
presented a myocardial infarction successfully treated by
angioplasty and a drug-eluting stent. The treatment with
PGZ was maintained with a favorable evolution. We did
not found any other cases with RGZ or PGZ, whereas
26 myocardial infarctions potentially related to drugs
were reported in the population of diabetic patients in
this study. Two meta-analyses have suggested that RGZ
increases the risk of myocardial infarction but did not
reach statistical significance for cardiovascular death
[14,15], but the reviews published in 2010 led to the
rosiglitazone withdrawal from the European market in
September 2010. The final results of the RECORD trial,
which compared cardiovascular outcomes in patients
with type 2 diabetes treated with RGZ and metformin
or sulfonylurea, confirm the increasing risk of heart fail-
ure with RGZ, but do not identify any statistically signif-
icant differences in the overall risk of cardiovascular
morbidity or mortality [16]. Lincoff’s meta-analysis on
the effect of PGZ on ischemic cardiovascular events
found that PGZ is associated with a significantly lower
risk of death, myocardial infarction, or stroke [17]. In
their review of the literature in order to estimate the
association between hypoglycemic agents and morbidity
and mortality in patients with heart failure and diabetes,
Eurich et al [18] concluded that metformin is the only
hypoglycemic agent not associated with harm in patients
with heart failure. A nested case-control study in older
patients found that both PGZ and RGZ were associated
with an increased risk of congestive heart failure, acute
myocardial infarction, and mortality when compared to
other combinations of oral hypoglycemic agents [19].
Cases of hepatotoxicity with second generation TZDs
have been few in number and less severe when com-
pared to troglitazone [2,20]. Troglitazone, unlike PGZ
and RGZ, induces the cytochrome P450 isoform 3A4,
which is partly responsible for its metabolism, and may
be prone to drug interactions. Floyd et al examined
reports of liver failure reported to the FDA during
Table 3 Results of the multiple logistic regression models
concerning the association between TZD exposure and 4
ADRs: Heart Failure, Myocardial Infarction, Edema and
Hepatitis
Heart failure Odds
ratio
(95% CI) P
Age 1.04 (0.99 - 1.09) 0.0705
Obesity 5.69 (1.34 - 24.20) 0.0185
Thiazolidinediones 65.39 (17.678 - 241.93) <0.0001
Hosmer and Lemeshow procedure 0.32
Myocardial infarction
Age 0.97 (0.95 - 1.00) 0.1076
Gender 1.73 (0.78 - 3.84) 0.1727
Thiazolidinediones 0.42 (0.05 - 3.17) 0.4039
Heart valve disorders 25.95 (2.63 - 255.47) 0.0053
Hypertension 0.34 (0.09 - 1.19) 0.0929
Hosmer and Lemeshow procedure 0.8254
Edema
Obesity 1.89 (0.58 - 6.17) 0.2863
Thiazolidinediones 25.09 (13.50 - 46.63) <0.0001
Biguanides 0.42 (0.20 - 0.87) 0.02
Hosmer and Lemeshow procedure 0.8043
Hepatitis
Age 0.99 (0.97 - 1.00) 0.1167
Angina pectoris 0.43 (0.13 - 1.39) 0.1620
Cardiac arrhythmia 0.36 (0.08 - 1.52) 0.1686
Cardiac insufficiency 0.58 (0.25 - 1.37) 0.2217
Thiazolidinediones 0.84 (0.40 - 1.78) 0.6645
Non Steroidal Anti-
Inflammatory Drugs
1.85 (1.13 - 3.01) 0.0134
Diuretics 0.58 (0.32 - 1.06) 0.0796
Calcium inhibitors 0.63 (0.32 -1.23) 0.1798
Angiotensin II inhibitors 0.68 (0.35 - 1.32) 0.2804
Hosmer and Lemeshow procedure 0.4397
Potential confounding factors retained in the final model are indicated in the
first column.
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observed with RGZ or PGZ was about 17 times higher
than the background rate for idiopathic acute liver fail-
ure in the general population [21]. By contrast, in our
study, we did not find any association between hepatitis
and TZD in comparison with other drugs used for dia-
betes. Even if no reliable estimates of the background
rate of liver failure in diabetic patients are available in
the literature, some have postulated that liver disease
m a yb em o r ef r e q u e n ti nt h i sp o p u l a t i o nw i t ho b e s i t y
and insulin resistance, due to non-alcoholic steato-hepa-
titis [2]. Moreover, this population may be exposed to
other drugs, some of which are suspected to increase
the risk of hepatic injuries [22], as observed in our data
with NSAID.
Some limitations of our study should be discussed.
First, limitations are due to the spontaneous reporting
system itself, although the reporting rate in France is
one of the highest among the European countries
[23,24]. Given the small number of patients treated by
TZDs in France, the number of ADR reports with TZD
is relatively low, in comparison with the results obtained
through the Health Canada’s spontaneous adverse event
reporting system (195 ADR with pioglitazone and 830
with rosiglitazone up to September 2006) [25]. Underre-
porting can affect validity of results since it can be
related either to the drug or to the degree of seriousness
of reactions. We did not find any case of myocardial
infarction or fracture related to TZD in the database.
This is not surprising, since in any spontaneous report-
ing system, clinicians are unlikely to report this kind of
event related to TZD, and instead attribute them to the
baseline risk of type 2 diabetes. The absence of fractures
reported to the French pharmacovigilance system does
not mean that this risk is not real. As demonstrated in
the meta-analysis of 10 randomized controlled trials and
2 observational studies, long-term use of TZD doubles
the risk of fractures among women with type 2 diabetes,
without a significant increase in the risk of fractures in
diabetic men [26]. In our study, reported ADRs in the
exposed population has increased year by year since the
marketing authorization of TZDs in France. This
increase can be explained by the increased use of TZDs
but also biased by reports related to the notoriety of
TZD ADRs. This last point is limited as reports with
TZD seem to be less frequently serious than for other
diabetic patients.
Populations of patients with specific disease identified
through the FPVD are very similar to that obtained
through population-based studies in France [27,28]. This
population of type 2 diabetic patients with ADR related
to their medications presents characteristics comparable
to those observed in other studies about French type 2
diabetes [29-31]: for example, we found that 11% of the
patients suffered from cardiac insufficiency, which is
very similar to the 12% observed in the ENTRED
national survey [30]. Moreover, the patterns of exposure
to drugs in this population are in agreement with the
guidelines for TZD use at the time of the study (in par-
ticular, TZDs are contraindicated with insulin and for
patients with NYHA class I to IV). In our study, patients
exposed to TZDs were less likely to present risk factors
of heart failure and cardiovascular comorbidities, 5.6%
had a cardiac insufficiency, and less than 3% were trea-
ted concomitantly with insulin.
Conclusions
In the French Pharmacovigilance database, adverse drug
reactions reported in diabetic patients exposed to thia-
zolidinediones (rosiglitazone and pioglitazone) present a
degree of seriousness similar to that observed with other
anti diabetic drugs. Thiazolidinediones exposure is asso-
ciated with an increased risk of edema and heart failure
in patients with type 2 diabetes even when recommen-
dations for use are respected, and this risk concerns
much rosiglitazone as pioglitazone. In contrast, the risk
of hepatic reactions and myocardial infarction, which
has been discussed with this class of drugs, is not higher
than with other hypoglycemic agents.
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